Astellas Pharma Stock Today
| ALPMY Stock | USD 10.05 0.02 0.20% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Astellas Pharma is trading at 10.05 as of the 21st of November 2024; that is 0.2 percent decrease since the beginning of the trading day. The stock's open price was 10.07. Astellas Pharma has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Astellas Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of December 2022 and ending today, the 21st of November 2024. Click here to learn more.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. The company has 1.83 B outstanding shares. More on Astellas Pharma
Moving together with Astellas Pink Sheet
| 0.75 | LLY | Eli Lilly | PairCorr |
| 0.8 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.82 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.71 | RHHBY | Roche Holding | PairCorr |
| 0.76 | RHHVF | Roche Holding AG | PairCorr |
Moving against Astellas Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Astellas Pink Sheet Highlights
| President | Yoshitsugu Shitaka |
| Business Concentration | Drug Manufacturers—General, Healthcare (View all Sectors) |
Astellas Pharma [ALPMY] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Large-Cap' category with a current market capitalization of 26.53 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Astellas Pharma's market, we take the total number of its shares issued and multiply it by Astellas Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Astellas Pharma classifies itself under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 1.83 B outstanding shares.
Astellas Pharma has accumulated about 336.76 B in cash with 257.44 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 184.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Astellas Pharma Probability Of Bankruptcy
Ownership AllocationAstellas Pharma holds a total of 1.83 Billion outstanding shares. Almost 99.97 percent of Astellas Pharma outstanding shares are held by general public with 0.03 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Astellas Ownership Details
Astellas Pharma Risk Profiles
| Mean Deviation | 1.32 | |||
| Standard Deviation | 1.78 | |||
| Variance | 3.18 | |||
| Risk Adjusted Performance | (0.08) |
Astellas Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Astellas Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Comparator Now
Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account |
| All Next | Launch Module |
Astellas Pharma Corporate Management
| Minoru Kikuoka | CFO Officer | Profile | |
| Naoki BSc | Chief VP | Profile | |
| Kenji Yasukawa | Senior Executive Officer, Manager of Vaccine Business Promotion Office | Profile | |
| Stig Ogata | VP Communications | Profile | |
| Katsuyoshi Sugita | Chief Officer | Profile |
Additional Tools for Astellas Pink Sheet Analysis
When running Astellas Pharma's price analysis, check to measure Astellas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astellas Pharma is operating at the current time. Most of Astellas Pharma's value examination focuses on studying past and present price action to predict the probability of Astellas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astellas Pharma's price. Additionally, you may evaluate how the addition of Astellas Pharma to your portfolios can decrease your overall portfolio volatility.